US 12,410,228 B2
Insulin analogs
John Gerbrandt Tasman Menting, Bulleen (AU); Brian Smith, Bundoora (AU); Danny Hung-Chieh Chou, Salt Lake City, UT (US); Helena Safavi-Hemami, Salt Lake City, UT (US); Michael Colin Lawrence, Newport (AU); and Baldomero M. Olivera, Salt Lake City, UT (US)
Assigned to UNIVERSITY OF UTAH RESEARCH FOUNDATION, Salt Lake City, UT (US); and THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, Parkville (AU)
Filed by UNIVERSITY OF UTAH RESEARCH FOUNDATION, Salt Lake City, UT (US); and THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, Parkville (AU)
Filed on Jan. 4, 2022, as Appl. No. 17/568,698.
Application 17/568,698 is a continuation of application No. 16/319,450, granted, now 11,248,034, previously published as PCT/AU2017/050758, filed on Jul. 21, 2017.
Claims priority of provisional application 62/483,118, filed on Apr. 7, 2017.
Claims priority of application No. 2016902883 (AU), filed on Jul. 22, 2016.
Prior Publication US 2022/0340636 A1, Oct. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/62 (2006.01); C07K 14/435 (2006.01); C30B 7/02 (2006.01); C30B 29/58 (2006.01); G16B 15/00 (2019.01); A61K 38/00 (2006.01); A61P 3/10 (2006.01)
CPC C07K 14/62 (2013.01) [C07K 14/43509 (2013.01); C30B 7/02 (2013.01); C30B 29/58 (2013.01); G16B 15/00 (2019.02); A61K 38/00 (2013.01); A61P 3/10 (2018.01); C07K 2299/00 (2013.01)] 18 Claims
 
1. An insulin analog comprising a human insulin A chain peptide at least 85% identical to wild-type human insulin A chain provided as SEQ ID NO: 24, and a human insulin B chain peptide comprising 90% identity to amino acids 1-22 of wild-type human insulin B chain provided as SEQ ID NO:25 and lacking the last 8 amino acids of the C-terminus of wild-type human insulin B chain, wherein the human insulin B chain peptide comprises a substitution at amino acid 10 and amino acid 20, wherein the substitution at amino acid 20 is G20Y, G20F, or G20P, and wherein the substitution at amino acid 10 is H10E, H10D or H10Q.